Sepsis Therapeutics - Global Strategic Business Report 2015-2022 with Select Sepsis Therapeutics Under Pipeline in 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Sepsis Therapeutics - Global Strategic Business Report" report to their offering.

This report analyzes the worldwide markets for Sepsis Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, and Rest of World. Annual estimates and forecasts are provided for the period 2017 through 2022. Market data and analytics are derived from primary and secondary research.

The report profiles 37 companies including many key and niche players such as

  • Adrenomed AG (Germany)
  • AM-Pharma B.V. (Netherlands)
  • Aridis Pharmaceuticals, Inc. (US)
  • Asahi Kasei Pharma America (US)
  • Astellas Pharma Inc. (Japan)
  • Bristol-Myers Squibb Company (US)
  • Chong Kun Dang BiO Corp. (South Korea)
  • Endacea, Inc. (US)
  • InflaRx GmbH (Germany)
  • Opsona Therapeutics Ltd. (Ireland)
  • Opsonix, Inc. (US)
  • T2 Biosystems, Inc. (US)
  • TaiRx, Inc. (US)
  • TiGenix NV (Belgium)

Key Topics Covered:

1. INDUSTRY OVERVIEW

  • Sepsis
  • A Prelude
  • Lack of Dedicated Sepsis Therapeutics
  • List of Sepsis Drug Candidates Discontinued from Development or Withdrawn from the Market (As of 2016)
  • Competition and Pipeline
  • Current Categories of Antibacterial Agents for First-line Sepsis Treatment
  • Select Sepsis Therapeutics under Pipeline: 2016
  • Current & Future Analysis
  • Growth Drivers in a Nutshell:
  • Market Restraints:
  • Overhaul of Clinical Trial Strategy Needed
  • Novel Immune-Specific Modes of Action Under Focus
  • Drug Resistance: The Major Threat to Sepsis Standby Antibiotics
  • Aging Population Statistics: Key Opportunity Indicator for Sepsis Therapeutics

2. SEPSIS THERAPEUTICS INNOVATIONS

  • MDx for Sepsis
  • Practical Challenges Galore
  • T2Dx System: Enabling Rapid Diagnosis of Sepsis
  • CytoSorb®: Addressing Sepsis by Removal of Cytokines

3. SEPSIS: AN OVERVIEW

  • Sepsis
  • A Leading Killer
  • Risk Profile
  • Most Vulnerable Groups: Newborns and the Elderly
  • A Growing Threat in Hospital Environment
  • Types of Sepsis
  • SIRS
  • Uncomplicated Sepsis
  • Severe Sepsis
  • Septic Shock
  • Septicemia
  • Bacteremia
  • Mortality Rates

4. CLINICAL TRIALS

  • SciClone Pharmaceuticals Starts Phase 3 Trial of ZADAXIN for Sepsis
  • InflaRx Announces Positive Phase IIa Results of mAb IFX-1 for Septic Organ Dysfunction
  • TiGenix NV Receives 5.4M Grant from EC for Phase Ib/IIa Trial of SEPCELL
  • T2 Biosystems Announces Positive Results from Investigational Study on its T2Candida Panel
  • TiGenix NV Completes Phase I Trial of Cx611 in Sepsis Challenge Model

5. PRODUCT INTRODUCTIONS/APPROVALS

  • Thermo Fisher Scientific Receives FDA Clearance for B - R - A - H - M - S PCT
  • Response Biomedical's RAMP® Test Receives Health Canada Approval and CE Mark
  • Wyss Institute of Harvard University Improves its Sepsis Therapeutic Device
  • Immunexpress to Present Data on its SeptiCyte® Lab test for Sepsis Assessment
  • Deutsche Biotech Strengthens IP on its Sepsis Drug Candidate Adrecizumab
  • DSX Therapeutics and R&D Ab® Receive EU Patents for mAb-based Sepsis Therapy
  • Bruker Introduces IVD MALDI Sepsityper Kit for Rapid Identification of Sepsis Microbes
  • SRL Diagnostics Launches Sepsiscreen' Test to Diagnose Sepsis
  • Abbott's Infectious Pathogen-testing Platform IRIDICA Available in Europe
  • Arch Biopartners Introduces Sepsis Drug Candidate Metablok to its Pipeline

6. RECENT INDUSTRY ACTIVITY

  • Sepset Biosciences Spins off from CDRD
  • Cyon Therapeutics Acquires Rights on LGT-209 for Sepsis Treatment from Novartis
  • Luminex Corporation Acquires Nanosphere
  • bioMérieux to Collaborate with Sepsis Alliance
  • TiGenix Selects TFS International for its First Trial SEPCELL
  • Wyss Institute Launches its Startup Company Opsonix to Commercialize Sepsis Therapy
  • Curetis Enters into Distribution Agreement with Acumen
  • Tenax Therapeutics Partners with Sepsis Alliance
  • Biocartis and Microbiome Enter into Collaboration Agreement for Rapid Sepsis Assay
  • Vivione Biosciences to Acquire Sepsis Player Trillium Diagnostics
  • Inotrem Completes Series A Financing
  • TheraNova Spins out Sepsis Company Consano Medical

7. FOCUS ON SELECT GLOBAL PLAYERS

8. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 37

  • The United States (12)
  • Canada (4)
  • Japan (4)
  • Europe (11)
  • - France (1)
  • - Germany (4)
  • - The United Kingdom (1)
  • - Rest of Europe (5)
  • Asia-Pacific (Excluding Japan) (6)

For more information about this report visit http://www.researchandmarkets.com/research/frfqxm/sepsis

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs